𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin

✍ Scribed by Jennifer Lin; Jason P. Lott; Valerianna K. Amorosa; Carrie L. Kovarik

Book ID
116584504
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
158 KB
Volume
60
Category
Article
ISSN
1097-6787

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Prevalence and impact of occult hepatiti
Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin
✍ Marion Levast; Sylvie Larrat; Marie-Ange Thelu; Sandrine Nicod; AgnΓ¨s Plages; Al πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 95 KB πŸ‘ 2 views

## Abstract The prevalence of occult hepatitis B, defined by absence of HBsAg and HBV DNA, ranges widely in patients with hepatitis C. This may influence the treatment of hepatitis C and the severity of liver disease. Sensitive and specific real‐time PCR techniques are available commercially and ca

Merimepodib, pegylated interferon, and r
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders
✍ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 240 KB πŸ‘ 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a